Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ZYBT vs DBVT vs ALKS vs ATXG vs CLPS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ZYBT
Zhengye Biotechnology Holding Limited

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CN
Market Cap$45M
5Y Perf.-78.7%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.+367.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.83B
5Y Perf.+11.0%
ATXG
Addentax Group Corp.

Integrated Freight & Logistics

IndustrialsNASDAQ • CN
Market Cap$3M
5Y Perf.-48.9%
CLPS
CLPS Incorporation

Information Technology Services

TechnologyNASDAQ • HK
Market Cap$25M
5Y Perf.-28.6%

ZYBT vs DBVT vs ALKS vs ATXG vs CLPS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ZYBT logoZYBT
DBVT logoDBVT
ALKS logoALKS
ATXG logoATXG
CLPS logoCLPS
IndustryDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyIntegrated Freight & LogisticsInformation Technology Services
Market Cap$45M$1690.08T$5.83B$3M$25M
Revenue (TTM)$186M$0.00$1.56B$4M$299M
Net Income (TTM)$11M$-168M$153M$-7M$-4M
Gross Margin49.0%65.4%14.7%22.8%
Operating Margin8.8%12.3%-49.4%-1.4%
Forward P/E24.5x
Total Debt$86M$22M$70M$22M$34M
Cash & Equiv.$19M$194M$1.12B$325K$28M

ZYBT vs DBVT vs ALKS vs ATXG vs CLPSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ZYBT
DBVT
ALKS
ATXG
CLPS
StockJan 25May 26Return
Zhengye Biotechnolo… (ZYBT)10021.3-78.7%
DBV Technologies S.… (DBVT)100467.5+367.5%
Alkermes plc (ALKS)100111.0+11.0%
Addentax Group Corp. (ATXG)10051.1-48.9%
CLPS Incorporation (CLPS)10071.4-28.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: ZYBT vs DBVT vs ALKS vs ATXG vs CLPS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CLPS leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Alkermes plc is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. DBVT and ATXG also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ZYBT
Zhengye Biotechnology Holding Limited
The Income Angle

Among these 5 stocks, ZYBT doesn't own a clear edge in any measured category.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +100.5% vs ZYBT's -90.5%
Best for: momentum
ALKS
Alkermes plc
The Growth Play

ALKS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
  • -12.0% 10Y total return vs CLPS's -78.6%
  • Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs ATXG's -202.0%
Best for: growth exposure and long-term compounding
ATXG
Addentax Group Corp.
The Value Play

ATXG is the clearest fit if your priority is value.

  • Better valuation composite
Best for: value
CLPS
CLPS Incorporation
The Income Pick

CLPS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 3 yrs, beta 0.19, yield 14.7%
  • Beta 0.19, yield 14.7%, current ratio 1.58x
  • 15.2% revenue growth vs DBVT's -100.0%
  • Beta 0.19 vs ZYBT's 1.75
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthCLPS logoCLPS15.2% revenue growth vs DBVT's -100.0%
ValueATXG logoATXGBetter valuation composite
Quality / MarginsALKS logoALKS9.8% margin vs ATXG's -202.0%
Stability / SafetyCLPS logoCLPSBeta 0.19 vs ZYBT's 1.75
DividendsCLPS logoCLPS14.7% yield, 3-year raise streak, vs ZYBT's 5.3%, (3 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+100.5% vs ZYBT's -90.5%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

ZYBT vs DBVT vs ALKS vs ATXG vs CLPS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ZYBTZhengye Biotechnology Holding Limited

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
ATXGAddentax Group Corp.
FY 2024
Reportable Subsegments
100.0%$4M
CLPSCLPS Incorporation
FY 2025
Other Member
100.0%$894,598

ZYBT vs DBVT vs ALKS vs ATXG vs CLPS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGATXG

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ATXG's -2.0%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
RevenueTrailing 12 months$186M$0$1.6B$4M$299M
EBITDAEarnings before interest/tax-$112M$212M-$947,630-$1M
Net IncomeAfter-tax profit-$168M$153M-$7M-$4M
Free Cash FlowCash after capex-$151M$392M-$1M$0
Gross MarginGross profit ÷ Revenue+49.0%+65.4%+14.7%+22.8%
Operating MarginEBIT ÷ Revenue+8.8%+12.3%-49.4%-1.4%
Net MarginNet income ÷ Revenue+6.1%+9.8%-2.0%-1.3%
FCF MarginFCF ÷ Revenue+7.1%+25.1%-34.3%-2.3%
Rev. Growth (YoY)Latest quarter vs prior year+28.2%-7.9%+15.3%
EPS Growth (YoY)Latest quarter vs prior year+91.5%-4.1%-136.8%+75.8%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ATXG and CLPS each lead in 2 of 5 comparable metrics.

On an enterprise value basis, ZYBT's 9.2x EV/EBITDA is more attractive than ALKS's 17.0x.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
Market CapShares × price$45M$1690.08T$5.8B$3M$25M
Enterprise ValueMkt cap + debt − cash$55M$1690.08T$4.8B$25M$31M
Trailing P/EPrice ÷ TTM EPS-0.75x24.47x-0.40x-3.46x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple9.15x17.01x
Price / SalesMarket cap ÷ Revenue1.63x3.95x0.70x0.15x
Price / BookPrice ÷ Book value/share0.86x0.65x3.25x0.09x0.43x
Price / FCFMarket cap ÷ FCF22.89x12.14x4.72x
Evenly matched — ATXG and CLPS each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATXG's 1.03x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs CLPS's 2/9, reflecting strong financial health.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
ROE (TTM)Return on equity+3.3%-130.2%+8.8%-31.7%-6.1%
ROA (TTM)Return on assets+2.3%-89.0%+5.4%-19.4%-3.2%
ROICReturn on invested capital+3.0%+18.9%-2.9%-7.9%
ROCEReturn on capital employed+4.7%-145.7%+14.2%-3.9%-9.8%
Piotroski ScoreFundamental quality 0–954742
Debt / EquityFinancial leverage0.25x0.13x0.04x1.03x0.59x
Net DebtTotal debt minus cash$68M-$172M-$1.0B$22M$6M
Cash & Equiv.Liquid assets$19M$194M$1.1B$324,953$28M
Total DebtShort + long-term debt$86M$22M$70M$22M$34M
Interest CoverageEBIT ÷ Interest expense4.07x-189.82x32.30x-3.67x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $45 for ATXG. Over the past 12 months, DBVT leads with a +100.5% total return vs ZYBT's -90.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs ATXG's -65.0% — a key indicator of consistent wealth creation.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
YTD ReturnYear-to-date-13.5%+3.6%+23.8%-10.9%-10.9%
1-Year ReturnPast 12 months-90.5%+100.5%+15.2%-55.0%-9.4%
3-Year ReturnCumulative with dividends-79.9%+18.1%+13.2%-95.7%+0.0%
5-Year ReturnCumulative with dividends-79.9%-68.3%+61.7%-99.6%-69.2%
10-Year ReturnCumulative with dividends-79.9%-87.1%-12.0%-99.9%-78.6%
CAGR (3Y)Annualised 3-year return-41.4%+5.7%+4.2%-65.0%+0.0%
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and CLPS each lead in 1 of 2 comparable metrics.

CLPS is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than ZYBT's 1.75 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs ZYBT's 7.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
Beta (5Y)Sensitivity to S&P 5001.75x1.26x1.00x1.48x0.19x
52-Week HighHighest price in past year$13.79$26.18$36.60$27.90$1.88
52-Week LowLowest price in past year$0.68$7.53$25.17$0.37$0.80
% of 52W HighCurrent price vs 52-week peak+7.1%+75.3%+95.6%+18.1%+47.9%
RSI (14)Momentum oscillator 0–10053.547.460.545.446.8
Avg Volume (50D)Average daily shares traded264K252K2.2M157K15K
Evenly matched — ALKS and CLPS each lead in 1 of 2 comparable metrics.

Analyst Outlook

CLPS leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 134.8% upside for DBVT (target: $46) vs 31.5% for ALKS (target: $46). For income investors, CLPS offers the higher dividend yield at 14.69% vs ZYBT's 5.27%.

MetricZYBT logoZYBTZhengye Biotechno…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcATXG logoATXGAddentax Group Co…CLPS logoCLPSCLPS Incorporation
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$46.33$46.00
# AnalystsCovering analysts1528
Dividend YieldAnnual dividend ÷ price+5.3%+14.7%
Dividend StreakConsecutive years of raises1003
Dividend / ShareAnnual DPS$0.35$0.13
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%0.0%
CLPS leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CLPS leads in 1 (Analyst Outlook). 3 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

ZYBT vs DBVT vs ALKS vs ATXG vs CLPS: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is ZYBT or DBVT or ALKS or ATXG or CLPS a better buy right now?

For growth investors, CLPS Incorporation (CLPS) is the stronger pick with 15.

2% revenue growth year-over-year, versus -18. 9% for Addentax Group Corp. (ATXG). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ZYBT or DBVT or ALKS or ATXG or CLPS?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -99. 6% for Addentax Group Corp. (ATXG). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus ATXG's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ZYBT or DBVT or ALKS or ATXG or CLPS?

By beta (market sensitivity over 5 years), CLPS Incorporation (CLPS) is the lower-risk stock at 0.

19β versus Zhengye Biotechnology Holding Limited's 1. 75β — meaning ZYBT is approximately 796% more volatile than CLPS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 103% for Addentax Group Corp. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ZYBT or DBVT or ALKS or ATXG or CLPS?

By revenue growth (latest reported year), CLPS Incorporation (CLPS) is pulling ahead at 15.

2% versus -18. 9% for Addentax Group Corp. (ATXG). On earnings-per-share growth, the picture is similar: Addentax Group Corp. grew EPS -19. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ZYBT or DBVT or ALKS or ATXG or CLPS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -121. 8% for Addentax Group Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -43. 5% for ATXG. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ZYBT or DBVT or ALKS or ATXG or CLPS?

In this comparison, CLPS (14.

7% yield), ZYBT (5. 3% yield) pay a dividend. DBVT, ALKS, ATXG do not pay a meaningful dividend and should not be held primarily for income.

07

Is ZYBT or DBVT or ALKS or ATXG or CLPS better for a retirement portfolio?

For long-horizon retirement investors, CLPS Incorporation (CLPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 14. 7% yield). Both have compounded well over 10 years (CLPS: -78. 6%, ATXG: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ZYBT and DBVT and ALKS and ATXG and CLPS?

These companies operate in different sectors (ZYBT (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and ATXG (Industrials) and CLPS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ATXG is a small-cap quality compounder stock; CLPS is a small-cap high-growth stock. ZYBT, CLPS pay a dividend while DBVT, ALKS, ATXG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ZYBT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 2.1%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

ATXG

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
Run This Screen
Stocks Like

CLPS

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 13%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.